(Photo by Flickr user Sanofi Pasteur, used under a Creative Commons license)
As was the case with Ebola, the federal government is eager to jumpstart efforts to find an antidote to Zika.
Emergent BioSolutions was a recipient of funding for such an effort this week when it was awarded a task order from the Biomedical Advanced Research and Development Authority (BARDA) that could be valued at up to $21.9 million.
The order, which is the first from BARDA, calls on the Gaithersburg-based company to develop a Zika vaccine using a base provided by the federal agency, and manufacture enough to be used on human trials. According to the Washington Business Journal, some of that production could take place at the company’s Baltimore manufacturing site in Bayview once it scales up.
Due to its recent circulation in Brazil, the mosquito-borne disease is in the headlines due to the upcoming Olympic games in Rio. Publicly-traded Emergent was also among the regional players involved in Ebola vaccine development. At least one other Baltimore company, Pharos Biologicals, is also looking to develop a Zika vaccine.
University of Maryland awarded $200M for flu vaccine research
MICA Game Lab and Shock Trauma are developing VR games for spinal injury patients
UMBC and UMB are joining forces to protect and probe medical data
Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program
This JHU team is developing tools to assess newborn health
Medical education startup Osmosis raises $4M Series A
CareFirst, LifeBridge Health plan innovation center, fund for digital health startups
What Asymmetrik is doing to help lead healthcare’s digital transformation
Sign-up for daily news updates from Technical.ly Baltimore